Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Most patients with drug-resistant, true extramedullary myeloma had a response with talquetamab plus teclistamab. The incidence of adverse events of grade 3 or above was high and was consistent with previous observations for each agent as monotherapy. (Funded by Johnson & Johnson; RedirecTT-1 ClinicalTrials.gov number, NCT04586426.).
Authors
- Moshe E. Gatt (ORCID: https://orcid.org/0000-0002-9426-4482)
- Emma Scott (ORCID: https://orcid.org/0000-0001-7854-9982)
- Nicholas T. Au
- Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
- Laura Rosiñol (ORCID: https://orcid.org/0000-0002-2534-9239)
- M Festa
- Todd Henninger
- Shahzad Raza (ORCID: https://orcid.org/0000-0002-2739-2265)
- Hila Magen (ORCID: https://orcid.org/0000-0002-3990-394X)
- Jing Christine Ye
- Shebli Atrash (ORCID: https://orcid.org/0000-0003-4547-7534)
- Dok Hyun Yoon
- Eva Medvedova (ORCID: https://orcid.org/0000-0003-2612-4303)
- Michael P. Chu (ORCID: https://orcid.org/0000-0002-2826-3342)
- Tadao Ishida (ORCID: https://orcid.org/0000-0003-3219-3292)
- Yael Chava Cohen (ORCID: https://orcid.org/0000-0002-9061-7287)
- Jiashen Lu
- Paula Rodríguez‐Otero (ORCID: https://orcid.org/0000-0001-5236-7785)
- Suzanne Trudel (ORCID: https://orcid.org/0000-0001-7952-6352)
- Christoph Heuck
- Maria Krevvata
- Hang Quach (ORCID: https://orcid.org/0000-0002-4796-3352)
- Lin Huang (ORCID: https://orcid.org/0000-0002-4892-7871)
- Lixia Pei
- Jenny Zhang (ORCID: https://orcid.org/0000-0003-0973-1785)
- Joshua R. Richter (ORCID: https://orcid.org/0000-0003-1860-3590)
- Lisa O’Rourke
- Hun Chuah
- Shaji Kumar
- Jeffrey Matous
- Koichi Onodera
- Jiangxiu Zhou
- Mikihiro Takamoto
- María-Victoria Mateos
- Payal Thakkar
Institutions
- Ulsan College (KR)
- Alberta Health Services (CA)
- Cleveland Clinic (US)
- Johnson & Johnson (United States) (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Oregon Health & Science University (US)
- The University of Melbourne (AU)
- Universidad de Salamanca (ES)
- Hebrew University of Jerusalem (IL)
- Royal Perth Hospital (AU)
- Tel Aviv Sourasky Medical Center (IL)
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Asan Medical Center (KR)
- WinnMed (US)
- Princess Margaret Cancer Centre (CA)
- University of Ulsan (KR)
- St Vincent's Hospital Melbourne (AU)
- Tohoku University Hospital (JP)
- Mount Sinai Medical Center (US)
- Levine Cancer Institute (US)
- Sarah Cannon (US)
- Japanese Red Cross Medical Center (JP)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Colorado Blood Cancer Institute (US)
- Clinica Universidad de Navarra (ES)
- Johnson & Johnson (Israel) (IL)
- Centro de Investigación del Cáncer (ES)
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson (Netherlands) (NL)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1056/nejmoa2514752
- Citations
- 6
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.62